Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis

Hong-Ki Min¹, Hyonjoung Cho² and Sung-Hwan Park³, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Armed Forces Capital hospital, Armed Forces Medical Command, Seongnam, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: axial spondyloarthritis, MRI, nonsteroidal antiinflammatory drugs (NSAIDs) and treatment

Session Information

Date: Tuesday, October 23, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The purpose of the present study was to examine the therapeutic effect of NSAIDs on active inflammatory lesions (bone marrow oedema [BMO]) in the sacroiliac(SI) joint in early axial spondyloarthritis (SpA). The aim was to propose optimal duration of treatment in initially diagnosed axial SpA patients with a good response to NSAIDs.

Methods: We enrolled 19 patients with axial SpA who were initially diagnosed in our hospital, and prescribed full-dose NSAIDs for 12 weeks. Twelve patients completed the 12-week protocol. We collected demographic, clinical, laboratory, and radiologic data at the time of enrolment and after 6 and 12 weeks of NSAID treatment. Baseline, 6-week, and 12-week data were compared using the Friedman test.

Results: The total SPondyloArthritis Research Consortium of Canada (SPARCC) score decreased significantly at 6 and 12 weeks (P value for 6 weeks and 12 weeks, 0.001, 0.025, respectively). The SPARCC score was significantly correlated with the ESR and CRP (P value for ESR and CRP, 0.041, 0.001, respectively). Univariate and multivariate regression analyses showed that the body mass index was significantly associated with changes in the SPARCC score.

Conclusion: Active inflammation in the SIJ was significantly attenuated by 6 weeks of full-dose NSAIDs. The SPARCC score was well-correlated with CRP and ESR. Therefore, at least 6 weeks of full-dose NSAIDs can decrease active SIJ lesions, and initial full-dose NSAIDs may prevent further structural damage as shown by reverting early radiologic change (BMO).

Disclosure: H. K. Min, None; H. Cho, None; S. H. Park, None.

To cite this abstract in AMA style:

Min HK, Cho H, Park SH. Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/nonsteroidal-anti-inflammatory-drugs-attenuate-active-inflammatory-sacroiliac-joint-lesions-in-patients-with-early-axial-spondyloarthritis/. Accessed July 2, 2020.

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nonsteroidal-anti-inflammatory-drugs-attenuate-active-inflammatory-sacroiliac-joint-lesions-in-patients-with-early-axial-spondyloarthritis/